Formulations business recorded revenue of Rs 122 crore, with EBITDA margins improving to 21.6 per cent

Akums Drugs & Pharmaceuticals announced its financial results for the second quarter of FY26. The CDMO segment remained the key contributor with revenue of Rs 804 crore. Volumes for the CDMO vertical grew 7 per cent y-o-y, as against muted industry volume growth, reflecting Akums’ position as preferred CMDO partner in India. The domestic Branded Formulations business recorded revenue of Rs 122 crore, with EBITDA margins improving to 21.6 per cent, supported by focussed portfolio management. The Branded Export segment, although had seasonal impact from various countries, maintained healthy EBITDA margin of 24.5 per cent.

For the quarter ended September 30, 2025, Akums reported consolidated revenue of Rs 1,018 crore compared to Rs 1,024 crore in Q1 FY26 and Rs 1,033 crore in Q2 FY25. The EBITDA stood at Rs 94 crore with a margin of 9.3 per cent. The PAT was Rs 43 crore. For the first half of FY26, revenue stood at
Rs 2,042 crore with an EBITDA of Rs 223 crore (margin of 10.9 per cent) and PAT of Rs 107 crore.

Sanjeev Jain, Managing Director, Akums Drugs & Pharmaceuticals, said: “Our performance this quarter reflects our focus on long-term priorities in a dynamic business environment. The developments in Zambia and Europe mark important milestones in our ongoing journey of becoming a global CDMO.”

Sandeep Jain, Managing Director, Akums Drugs & Pharmaceuticals, added, “CDMO business is navigating through a complex phase, with continued weakening of API prices and sustained flat volumes in the industry. Akums has outpaced industry volume growth. we remain focused on delivering long term shareholder value by further cementing our leadership position in CDMO business, taking measures to grow our domestic and exports branded business and curtailing losses in API and trade generics.”